Skip Navigation

European Heart Journal 2002 23(4):301-307; doi:10.1053/euhj.2001.2778
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tavendale, R.
Right arrow Articles by Tunstall-Pedoe, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tavendale, R.
Right arrow Articles by Tunstall-Pedoe, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events. The Scottish Heart Health Study Cohort

R. Tavendalea,f1, D. Parrattb, S.D. Pringlec, R. A'brooka and H. Tunstall-Pedoea

a Cardiovascular Epidemiology Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, U.K.
b Infection and Immunity, Department of Molecular and Cellular Pathology, University of Dundee, Ninewells Hospital and Medical School, Dundee, U.K.
c Department of Cardiology, Ninewells Hospital and Medical School, Dundee, U.K.

revised April 24, 2001; accepted May 2, 2001

Abstract

Aims To investigate the relationship between serum markers of Chlamydia pneumoniae infection and subsequent coronary events.

Methods and Results In a nested case-control study, based on the Scottish Heart Health Study cohort, we estimated IgG, IgA and IgM antibodies to C. pneumoniae, and circulating immune complexes containing C. pneumoniae antigen in baseline serum samples from 217 cases experiencing a subsequent coronary event during follow-up (mean 7·5 years) and from their matched controls. In men, the proportion of specimens positive for IgG, IgA and IgM antibodies showed no case-control differences (80% vs 80%, 57% vs 53% and 3% vs 3%, respectively). The odds ratio for a coronary event was 1·00 (95% confidence interval 0·59–1·69) for the presence of IgG antibodies to C. pneumoniae; 1·21 (0·76–1·92) for IgA and 0·75 (0·17–3·35) for IgM. Similar results were seen in women. The proportion of specimens with circulating immune complexes with C. pneumoniae antigen also showed no case-control differences (12% vs 12%, both sexes combined) with an odds ratio of 1·00 (0·57–1·76).

Conclusion Prior infection with C. pneumoniae, as estimated by these markers, does not appear to be a risk factor for subsequent coronary heart disease.

Key Words: Coronary artery disease • Chlamydia pneumoniae infection • epidemiology • immune complexes

f1 Correspondence: Roger Tavendale, PhD, Cardiovascular Epidemiology Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, U.K.

References

  1. Weissberg PL. Atherogenesis: current understanding of the causes of atheroma. Heart. 2000;83:247–252[Free Full Text]
  2. Wong Y-K, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart. 1999;81:232–238[Abstract/Free Full Text]
  3. Saikku P, Leinonen M, Mattila M. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;ii:983–985
  4. Kuo C-C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841–849[Web of Science][Medline]
  5. Kuo C-C, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501–1504[Abstract/Free Full Text]
  6. Muhlestein JB, Hammond EH, Carlquist JF. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555–1561[Abstract]
  7. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407[Abstract/Free Full Text]
  8. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407[CrossRef][Web of Science][Medline]
  9. Anderson JL, Muhlestein JB, Carlquist J. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation. 1999;99:1540–1547[Abstract/Free Full Text]
  10. Smith WCS, Crombie IK, Tavendale R, Irving JM, Kenicer MB, Tunstall-Pedoe H. The Scottish Heart Health Study; objectives and development of methods. Health Bull. 1987;45:211–217
  11. Tunstall-Pedoe H. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105–114[CrossRef][Web of Science][Medline]
  12. Smith WCS, Crombie IK, Tunstall-Pedoe H. Ayrshire and Arran coronary prevention programme—baseline risk factor survey. Health Bull. 1989;47:227–233
  13. Carstairs, V, Morris, R, Deprivation and health in Scotland, Aberdeen, Aberdeen University Press, 1991
  14. Tunstall-Pedoe H, Kuulasmaa KK, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project—Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in 4 continents. Circulation. 1994;90:
  15. Casali P, Bossus A, Carpentier NA, Lambert PH. Solid phase immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: Conglutinin binding test. Clin Exp Immunol. 1977;29:342–354[Web of Science][Medline]
  16. Tunstall-Pedoe, H, Woodward, M, Tavendale, R, A'Brook, R, McCluskey, MK, Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. 1998 BMJ, 315, 722, 9
  17. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang S-P, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease. The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1999;150:149–156[Abstract/Free Full Text]
  18. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 1999;99:1161–1164[Abstract/Free Full Text]
  19. Strachan DP, Carrington D, Mendall MA. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ. 1999;318:1035–1040[Abstract/Free Full Text]
  20. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ. 2000;321:204–207[Abstract/Free Full Text]
  21. Danesh J, Whincup P, Walker M. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ. 2000;321:208–213[Abstract/Free Full Text]
  22. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titres to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med. 1999;131:573–577[Abstract/Free Full Text]
  23. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827–832[Abstract/Free Full Text]
  24. Puolakkainen M, Kuo C-C, Shor A, Wang S-P, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 1993;31:2212–2214[Abstract/Free Full Text]
  25. Davidson M, Kuo C-C, Middaugh JP. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998;98:628–633[Abstract/Free Full Text]
  26. Wong Y-K, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol. 1999;34:1435–1439[Abstract/Free Full Text]
  27. Dechend R, Maass M, Gieffers J. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-{kappa}B and induces tissue factor and PAI-1 expression. Circulation. 1999;100:1369–1373[Abstract/Free Full Text]
  28. Rodel J, Woytas M, Groh A. Production of basic fibroblast growth factor and interluekin 6 by human smooth muscle cells following infection withChlamydia pneumoniae. Infect Immun. 2000;68:3635–3641[Abstract/Free Full Text]
  29. Moazed TC, Kuo C-C, Grayston JT. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis. 1997;175:883–890[Web of Science][Medline]
  30. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48–52[Abstract]
  31. Torgano G, Cosentini R, Mandelli C. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation. 1999;99:1555–1559[Abstract/Free Full Text]
  32. Leinonen M, Linnanmaki E, Mattila K. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog. 1990;9:67–73[CrossRef][Web of Science][Medline]
  33. Saikku P, Leinonen M, Tenkanen L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Int Med. 1992;116:273–278[Abstract/Free Full Text]
  34. Glader CA, Boman J, Saikku P. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae -specific IgG antibodies. Eur Heart J. 2000;21:639–646[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
J. Parratt, R. Tavendale, J. O'Riordan, D. Parratt, and R. Swingler
Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 292 - 299.
[Abstract] [PDF]

Home page
 Infect. Immun.Home page
M. P. Kim, C. A. Gaydos, B. J. Wood, J. P. Hardick, Y. Zhang, and L. M. Wahl
Chlamydia pneumoniae Enhances Cytokine-Stimulated Human Monocyte Matrix Metalloproteinases through a Prostaglandin E2-Dependent Mechanism
Infect. Immun., January 1, 2005; 73(1): 632 - 634.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
M. J. Zibaeenezhad, A. Amanat, A. Alborzi, and A. Obudi
Relation of Chlamydia Pneumoniae Infection to Documented Coronary Artery Disease in Shiraz, Southern Iran
Angiology, January 1, 2005; 56(1): 43 - 48.
[Abstract] [PDF]

Home page
 HeartHome page
A M A Shehab, R J MacFadyen, M McLaren, R Tavendale, J J F Belch, and A D Struthers
Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study
Heart, November 1, 2004; 90(11): 1263 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. Paldanius, A. Bloigu, M. Leinonen, and P. Saikku
Measurement of Chlamydia pneumoniae-Specific Immunoglobulin A (IgA) Antibodies by the Microimmunofluorescence (MIF) Method: Comparison of Seven Fluorescein-Labeled Anti-Human IgA Conjugates in an In-House MIF Test Using One Commercial MIF and One Enzyme Immunoassay Kit
Clin. Vaccine Immunol., January 1, 2003; 10(1): 8 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Saikku
Seroepidemiology in Chlamydia pneumoniae -- atherosclerosis association
Eur. Heart J., February 2, 2002; 23(4): 263 - 264.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tavendale, R.
Right arrow Articles by Tunstall-Pedoe, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tavendale, R.
Right arrow Articles by Tunstall-Pedoe, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?